Advertisement

Collaboration › Details
Medigene–Leucadia: investor conference, 201906 supply service Medigene presents at Jefferies Global Healthcare Conference NY
![]() |
Period | 2019-06-04 � 2019-06-07 |
![]() |
Region | New York, NY |
Country | United States (USA) | |
![]() |
Partner, 1st | Medigene AG (FSE: MDG1, Prime Standard) |
Group | Medigene (Group) | |
Partner, 2nd | Jefferies LLC | |
Group | Leucadia (Group) | |
![]() |
Product | Jefferies 2019 Global Healthcare Conference New York |
Product 2 | TCR engineered T-cells | |
![]() |
Person | Schendel, Dolores J. (Medigene 201602– CEO before CMO before Trianta Immunotherapies + HelmholtzZentrum München) |
Person 2 | Hofmann, Julia (MC Services 201910– before Medigene) | |
Medigene AG. (5/8/19). "Press Release: Medigene Participates at Upcoming Conferences". Martinsried.
Medigene AG (FSE: MDG1, Prime Standard) today announced its participation at the following upcoming scientific, business development and investor conferences:
EACR-ESMO Joint Conference on Liquid Biopsies
Date: 15 - 17 May 2019
Location: Bergamo, Italy
CIMT Annual Meeting
Date: 21 - 23 May 2019
Location: Mainz, Germany
Prof. Dolores J. Schendel, CEO of Medigene AG, will give a presentation on the topic "Matching future needs for world patient populations needing TCR-T therapies with different antigen specificities and HLA restrictions" on 23 May.
ASCO - American Society of Clinical Oncology - Annual Meeting
Date: 01 - 05 June 2019
Location: Chicago, USA
BIO International Convention
Date: 03 - 06 June 2019
Location: Philadelphia, USA
Jefferies Global Healthcare Conference
Date: 04 - 07 June 2019
Location: New York/USA
Prof. Dolores J. Schendel, CEO of Medigene AG, is invited to give a company presentation.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit http://www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com
Record changed: 2019-05-21 |
Advertisement

More documents for Medigene (Group)
- [1] Medigene AG. (1/28/21). "Press Release: Focus on Solid Tumors – Discontinuation of MDG1021 Development Program". Planegg-Martinsried....
- [2] Medigene AG. (1/13/21). "Press Release: Medigene Expands Patent Protection of Its Technologies in Key Markets, the USA and Europe". Planegg-Martinsried....
- [3] Medigene AG. (11/12/20). "Press Release: Medigene Provides Q3 2020 Update". Planegg-Martinsried....
- [4] Medigene AG. (10/19/20). "Press Release: Medigene and Cytovant Enter into Service Agreement for DC Vaccine Manufacturing Process Development". Planegg-Martinsried....
- [5] Medigene AG. (9/22/20). "Press Release: Strategic Measures including Restructuring with Extension of Cash Runway and Improved EBITDA". Planegg....
- [6] Medigene AG. (3/26/20). "Press Release: Medigene Provides Results for Fiscal Year 2019 and Outlook". Martinsried....
- [7] Imcyse. (8/5/19). "Press Release: Imcyse Announces Changes in Management and Board, Appoints Thomas Taapken as Executive Chairman". Liège....
- [8] Medigene AG. (5/14/19). "Press Release: Medigene Reports Financial & Business Results for the First Three Months of 2019". Martinsried....
- [9] Medigene AG. (5/9/19). "Press Release: Bluebird Presents Preclinical Data of First TCR Candidate from Medigene Collaboration. Start Clinical Development 2020". Martinsried....
- [10] Medigene AG. (5/8/19). "Press Release: Medigene Participates at Upcoming Conferences". Martinsried....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top